Focus is a rapidly growing, privately owned, generic pharmaceutical company. Now part of the Concordia Group
News and press
Focus successful in UK litigation against Novartis concerning Voleze® Rivastigmine Transdermal Patches
Founded in 2003, Focus has achieved significant growth since formation, and in 2014 is achieving sales in excess of £30m. Such dynamic growth, in the highly competitive UK market, is achieved through a highly experienced sales team and selective product choice. Focus specialise in the licensing and marketing of generic products in the UK. The company’s range currently comprises of over 60 different molecules, ranging across almost all different types of formulation and therapeutic areas. As well as developing and maintaining its licences, the Focus technical team ensure that Focus is fully compliant with all the relevant regulations relating to GMP, GDP, GCP and PV. Focus has the proven ability to achieve profitable generic sales in the highly competitive UK generic market. It successfully markets both its own products and also works with a number of generic and brand companies managing their products in the UK. Focus is a member of the British Generic Manufacturers Association (BGMA).
Focus was acquired by AMCo in October 2014.